marked.bio

BCL-2 inhibitor · small molecule

venetoclax

43 active trials across 6 of our biomarkers, targeting BCL-2. Not approved for any biomarker on marked.bio yet.

Also known as ABT-199, Venclexta, Venclyxto.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
FLT3 mutation (ITD/TKD) 17 22 Phase 2/3
NPM1 mutation 15 18 Phase 3
IDH1/2 mutation 14 16 Phase 3
KRAS G12C 2 3 Phase 2
KRAS G12D 2 3 Phase 2
ALK fusion 1 2 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of venetoclax.

  1. Kura Oncology 2
  2. Johnson & Johnson 2
  3. Sellas Life Sciences Group 1
  4. Eli Lilly 1
  5. Astellas 1
  6. Sumitomo Pharma America 1
  7. AbbVie 1

Trials

43 of 54 trials shown

  1. FLT3-ITD Targeted Therapy in Fit AML Patients

    Not yet recruiting Phase 2/3 European Organisation for Research and Treatment of Cancer - EORTC Started 2026Primary completion 2028-10 NCT07425808

    gilteritinib FDA EUvenetoclaxazacitidineLocal standard of care (SOC)

    FLT3-ITD mutation as per local IVDR-compliant testing.

    FLT3 mutation (ITD/TKD)AML (Acute Myeloid Leukemia)

  2. VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

    Not yet recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital Started 2026Primary completion 2029-02 NCT07407140

    gilteritinib FDA EUazacitidinevenetoclaxcytarabinedaunorubicinidarubicinRe-induction TherapyConsolidation TherapyMaintenance Therapy

    Documented FLT3-ITD or FLT3-TKD mutation by PCR or NGS

    FLT3 mutation (ITD/TKD)AML, Adult

  3. Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

    Recruiting Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland Started 2025Primary completion 2028-12 NCT07075016

    venetoclax

    Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML according to the 2022 International Consensus Classification…

    IDH1/2 mutationAcute Myeloid Leukemia

  4. Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

    Recruiting Phase 2/3 Ruijin Hospital Started 2025Primary completion 2030-03 NCT06972641

    decitabinesorafenibAvastinibvenetoclax

    ARM2 Initial bone marrow gene II sequencing showed FLT3-ITD mutation with or without NPM1 mutation, no TP53 mutation, and no AML/MR.

    FLT3 mutation (ITD/TKD)AML, MDS

  5. Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

    Recruiting Phase 3 Kura Oncology Started 2025Primary completion 2031-11 NCT07007312

    ziftomenib FDAvenetoclaxazacitidinedaunorubicincytarabine

    …nintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

    NPM1 mutationAcute Myeloid Leukemia (AML)

  6. A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

    Recruiting Phase 3 Johnson & Johnson Started 2025Primary completion 2029-06 NCT06852222

    bleximenibvenetoclaxazacitidine

    …d lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than or equal to (\> or =) 10% bone marrow bla…

    NPM1 mutationLeukemia, Myeloid, Acute

  7. Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

    Recruiting Phase 2/3 University Hospital, Angers Started 2015Primary completion 2025-07 NCT02416388

    idarubicindaunorubicincytarabineCyclosporinemethotrexateMycophenolic acid (MPA)vosaroxindexamethasonevenetoclax

    Genetic mutation testing of the FLT3 (FLT3-ITD ou FLT3-TKD) gene, performed in local or central laboratory

    FLT3 mutation (ITD/TKD)NPM1 mutationAcute Myeloid Leukemia (AML)

  8. Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

    Not yet recruiting Phase 2 National Cancer Institute (NCI) Starts 2027Primary completion 2027-12 NCT07862517

    azacitidinecytarabinedaunorubicinquizartinib FDA EUvenetoclax

    Patient must have newly diagnosed acute myeloid leukemia (AML) with FLT3 ITD mutation as assessed by central myeloMATCH testing with variant allele frequency (VAF) ov…

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia

  9. Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

    Recruiting Phase 2 Justin Watts, MD Started 2026Primary completion 2029-03 NCT06782542

    olutasidenib FDAvenetoclaxazacitidine

    Newly diagnosed AML Isocitrate dehydrogenase 1 (IDH1) R132 mutated disease as assessed locally.

    IDH1/2 mutationAcute Myeloid Leukemia, IDH1 Mutation

  10. Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

    Not yet recruiting Phase 2 National Cancer Institute (NCI) Started 2026Primary completion 2030-04 NCT07153497

    decitabineolutasidenib FDAvenetoclax

    …n the MYELOMATCH Master Screening and Reassessment Protocol (MSRP), determined to have an IDH1-R132 mutation and assigned to this trial via MATCHBox

    IDH1/2 mutationAcute Myeloid Leukemia, Myelodysplastic Syndrome

  11. A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2026Primary completion 2028-01 NCT07392242

    ivosidenib FDA EUazacitidinevenetoclax

    Participant has IDH1-R132 mutation present prior to initiating Ivo/Aza/Ven confirmed by CLIA approved local testing…

    IDH1/2 mutationAcute Myeloid Leukemia

  12. Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia

    Not yet recruiting Phase 1/2 Shanghai Jiao Tong University School of Medicine Started 2026Primary completion 2027-10 NCT07486726

    Aclarubicinvenetoclaxazacitidine

    … with relapsed/refractory AML after intensive chemotherapy (Exclude patients with FLT3 or IDH1/2 mutations who have not previously received targeted therapy).

    IDH1/2 mutationAcute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)

  13. Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

    Not yet recruiting Phase 1/2 University Hospital, Bordeaux Started 2026Primary completion 2027-09 NCT07726576

    venetoclaxmidostaurin FDA EU

    Documented FLT3 gene mutation (-TKD D835 or I836 or -ITD or both) FLT3-ITD is assessed by DNA fragment analysis.

    FLT3 mutation (ITD/TKD)Leukemia, Myeloid, Acute

  14. Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

    Recruiting Phase 2 National Cancer Institute (NCI) Started 2025Primary completion 2027-03 NCT06672146

    decitabineenasidenib FDAvenetoclax

    …x Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

    IDH1/2 mutationAcute Myeloid Leukemia

  15. Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

    Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital Started 2025Primary completion 2026-10 NCT06611839

    ivosidenib FDA EUvenetoclaxazacitidine

    Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

    IDH1/2 mutationAML, IDH1 Mutation, Treatment

  16. a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

    Recruiting Phase 2 The First Affiliated Hospital of Soochow University Started 2025Primary completion 2026-04 NCT07007949

    ivosidenib FDA EUvenetoclaxazacitidine

    a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

    IDH1/2 mutationAcute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib

  17. Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

    Recruiting Phase 2 M.D. Anderson Cancer Center Started 2025Primary completion 2027-06 NCT07032727

    olutasidenib FDAcladribinevenetoclaxgilteritinibRuxolitinibcytarabine

    Participants must have a documented IDH1 mutation.

    IDH1/2 mutationFLT3 mutation (ITD/TKD)Targeted Therapy, IDH1-Mutated Malignancies, Mutations

  18. Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

    Recruiting Phase 2 OHSU Knight Cancer Institute Started 2025Primary completion 2027-10 NCT06504459

    azacitidinecladribinecytarabinevenetoclax

    …ization (WHO), or active signaling mutated AML defined as AML with mutation(s) to N/KRAS, FLT3 ITD/TKD, NF1, PTPN11 or CBL

    FLT3 mutation (ITD/TKD)Acute Monocytic Leukemia, Acute Myeloid Leukemia

  19. Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

    Recruiting Phase 2 Technische Universität Dresden Started 2025Primary completion 2029-04 NCT06696183

    gilteritinib FDA EUvenetoclaxazacitidine

    FLT3 mutation at initial diagnosis

    FLT3 mutation (ITD/TKD)AML - Acute Myeloid Leukemia

  20. A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2025Primary completion 2027-01 NCT06773208

    azacitidinevenetoclax

    …disease (MRD) at or above a level of 0.1%, by flow cytometry (MFC) or in molecular cases (NPM1 mutated or one of the CBF translocations) RT-qPCR at or above 0.01%, as described above (see sect…

    NPM1 mutationAcute Myeloid Leukemia (AML)

  21. Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

    Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Started 2024Primary completion 2027-10 NCT06686108

    azacitidinedecitabinevenetoclax

    High risk subgroups based on NGS definition: PI3K signaling pathway/NRAS, KRAS/TP53/IKZF1/DNTM3A/IDH1, IDH2 gene mutation with or without NOTCH1, FBXW7/PHF6/EP300 gene mutation.

    KRAS G12CKRAS G12DIDH1/2 mutationT-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse

  22. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

    Recruiting Phase 2 National Cancer Institute (NCI) Started 2024Primary completion 2029-05 NCT06317649

    azacitidinegilteritinib FDA EUvenetoclax

    Patient must have the FLT3-ITD, D835, or I836del mutation based on MYELOMATCH Protocol

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia

  23. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

    Recruiting Phase 2 National Cancer Institute (NCI) Started 2024Primary completion 2027-12 NCT05554393

    azacitidinecytarabinedaunorubicinvenetoclax

    AML with FLT3-ITD mutation

    FLT3 mutation (ITD/TKD)NPM1 mutationAcute Myeloid Leukemia

  24. BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

    Recruiting Phase 1/2 Chen Suning Started 2024Primary completion 2025-12 NCT06746519

    venetoclaxazacitidine

    …gnosis according to the 2022 ELN Risk Stratification, as well as a defined combination of NPM1 mutation or NUP98 rearrangement or KMT2A rearrangement

    NPM1 mutationAcute Myeloid Leukemia

  25. Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

    Recruiting Phase 2 Technische Universität Dresden Started 2024Primary completion 2030-09 NCT05904106

    venetoclaxazacitidine

    Newly diagnosed CD33-positive AML with NPM1 mutation according to WHO criteria

    NPM1 mutationAcute Myeloid Leukemia

  26. Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

    Active, not recruiting Phase 2 Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias Started 2024Primary completion 2028-06 NCT06668558

    azacitidinevenetoclax

    In patients with NPM1 mutation, qRT-PCR of NPM1 will be the method used to establish a molecular failure, defined as fai…

    NPM1 mutationAcute Myeloid Leukemia

  27. A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

    Active, not recruiting Phase 1/2 Astellas Started 2023Primary completion 2028-07 NCT05520567

    gilteritinib FDA EUvenetoclaxazacitidine

    Participant is positive for FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication \[ITD\] and/or tyrosine kinase domain \[TKD\] \[D835/I836\] …

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia

  28. IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

    Recruiting Phase 2 Alice Mims Started 2022Primary completion 2027-09 NCT05401097

    azacitidineenasidenib FDAivosidenib FDA EUvenetoclax

    Patients with newly diagnosed IDH1 or IDH2 mutated AML

    IDH1/2 mutationAcute Myeloid Leukemia

  29. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    Recruiting Phase 1/2 Sumitomo Pharma America Started 2022Primary completion 2027-06 NCT04988555

    enzomenibazolesvenetoclaxgilteritinib FDA EUazacitidineIntensive chemotherapy with 7 + 3

    Have MLLr or NPM1m AND any of the following FLT3 mutations: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

    FLT3 mutation (ITD/TKD)NPM1 mutationLeukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

  30. A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

    Recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2022Primary completion 2026-12 NCT05360160

    revumenib FDAvenetoclaxdecitabine

    …d/refractory (R/R cohort) AML or myeloid phenotype MPAL with either KMT2Ar, or NUP98r, or NPM1c.

    NPM1 mutationAcute Myeloid Leukemia

  31. Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

    Recruiting Phase 1/2 Sellas Life Sciences Group Started 2021Primary completion 2026-12 NCT04588922

    SLS009venetoclaxazacitidine

    KRASmut: 1 point

    KRAS G12CKRAS G12DHematologic Malignancies

  32. Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    Recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2021Primary completion 2027-11 NCT04774393

    decitabineenasidenib FDAivosidenib FDA EUvenetoclax

    Subjects must have documented IDH1 or IDH2 gene mutation

    IDH1/2 mutationAcute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

  33. ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2021Primary completion 2028-01 NCT05010122

    decitabinegilteritinib FDA EUvenetoclax

    Phase I cohort: Adults \>= 18 years with relapsed/refractory FLT3-mutated AML or myelodysplastic syndrome (MDS) that is intermediate-2 or high-risk by the Internat…

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

  34. Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

    Recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2019Primary completion 2028-09 NCT04140487

    azacitidinegilteritinib FDA EUvenetoclax

    Phase I cohort: Adults ≥ 18 years with relapsed/refractory FLT3-mutated AML or CMML or other MDS/MPN that is intermediate-2 or high-risk by the International Pro…

    FLT3 mutation (ITD/TKD)Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia

  35. Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

    Recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2018Primary completion 2027-09 NCT03471260

    azacitidineivosidenib FDA EUvenetoclax

    IDH1-R132 mutated disease status as assessed by local laboratory. 2HG-producing IDH1 variants outside of R132 (i.e.

    IDH1/2 mutationAcute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm

  36. A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

    Recruiting Phase 1 M.D. Anderson Cancer Center Started 2025Primary completion 2028-12 NCT06448013

    venetoclaxgemtuzumab ozogamicinziftomenib FDA

    Presence of KMT2Ar, NUP98r, NPM1c, UBTF-ITD or other HOX pathway mutation.

    NPM1 mutationAcute Myeloid Leukemia

  37. CIML NK Cells With Venetoclax for AML

    Recruiting Phase 1 Dana-Farber Cancer Institute Started 2024Primary completion 2026-11 NCT06152809

    Cytokine-Induced Memory-like Natural Killer Cellsaldesleukinvenetoclax

    …ditional mutations associated with acquired resistance to venetoclax: Mutated NRAS, KRAS, FLT3 ITD/TKD

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid

  38. Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

    Recruiting Phase 1 St. Jude Children's Research Hospital Started 2024Primary completion 2027-01 NCT06177067

    revumenib FDAvenetoclaxazacitidinemethotrexatecytarabine

    Presence of KMT2A rearrangement (KMT2Ar), NUP98 rearrangement (NUP98r), NPM1 mutation or fusion, PICALM::MLLT10, DEK::NUP214, UBTF-TD, KAT6A rearrangement (KAT6Ar), or SET::NU…

    NPM1 mutationRefractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage

  39. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Recruiting Phase 1 Kura Oncology Started 2023Primary completion 2030-04 NCT05735184

    ziftomenibvenetoclaxazacitidinedaunorubicincytarabinequizartinib FDA EU

    Those intending treatment with intensive chemotherapy in Arm C should be NPM1-m and FLT3-ITD+ with an allelic ratio ≥0.05 and eligible for FLT3-targeted treatment

    FLT3 mutation (ITD/TKD)NPM1 mutationAcute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1

  40. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    Active, not recruiting Phase 1 AbbVie Started 2023Primary completion 2031-03 NCT05753501

    ABBV-101venetoclax

    … primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 re…

    ALK fusionHematologic Cancer

  41. A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

    Active, not recruiting Phase 1 Johnson & Johnson Started 2022Primary completion 2026-10 NCT05453903

    bleximenibvenetoclaxazacitidinecytarabinedaunorubicinidarubicin

    c) harboring KMT2A, NPM1, NUP98, or NUP214 alterations

    NPM1 mutationLeukemia, Myeloid, Acute

  42. Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

    Active, not recruiting Phase 1 Eli Lilly Started 2020Primary completion 2023-07 NCT04603001

    LY3410738venetoclaxazacitidine

    Advanced IDH mutant hematologic malignancy including:

    IDH1/2 mutationAcute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)

  43. UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

    Recruiting Early Phase 1 Baylor College of Medicine Started 2025Primary completion 2028-10 NCT07059975

    idarubicinfludarabinecytarabinevenetoclaxetoposideAsparaginase Erwinia Chrysanthemi (recombinant)Intrathecal triple

    Mutated NPM1

    NPM1 mutationAcute Myeloid Leukemia, Pediatric AML